Black & White Peptides Ltd. Registered in England & Wales, company number 16876162.
Retatrutide.
Price range: £80.00 through £160.00
A 39-amino-acid synthetic peptide acting at the GLP-1, GIP and glucagon receptors. Janoshik HPLC-verified. Vial or pen. Same-day UK dispatch. Real human reply on WhatsApp.
What’s in your box
How researchers begin Retatrutide
Pulled straight from Jastreboff et al. 2023 (NEJM). About the compound, not your order. Research use only.
Key Features
- Premium Research Peptides
- Secure Bank Payments
- Satisfaction Guarantee
- Worldwide Shipping
- Money Back Guarantee
Quick answers to the most-asked questions
Everything researchers usually message us about, answered on the page.
- 🛡 Are your products tested? Every batch undergoes Janoshik HPLC testing.
Yes – every batch. Every product we supply is independently HPLC-verified by Janoshik Analytical, a Czech specialist peptide-analysis laboratory unaffiliated with us. Reported purity is consistently above 99%.
Where a Janoshik report has been issued for the current batch, the printed Certificate of Analysis is supplied with the order. Otherwise the verification record is published on our Purity page.
Every COA carries a unique verification key you can authenticate against Janoshik’s own portal at janoshik.com – so you don’t have to take our word for it. We’re the only UK supplier writing publicly about how to read these reports: how to read a Janoshik HPLC report ›
- How to mix BAC + powder
- Wipe the vial top. Use one of the alcohol prep wipes from the box. Let it dry.
- Draw 2 mL BAC water. Use one of the insulin syringes. Insert the needle through the rubber stopper of the BAC water vial.
- Inject the BAC slowly down the inside wall of the peptide vial. Don’t squirt directly onto the powder.
- Swirl gently. Don’t shake. Wait 30 seconds for full dissolution. Refrigerate.
Use the reconstitution card on the inside of the box lid as your reference next time.
- How to use the pen
- Attach a fresh needle. Wipe the needle end of the pen with an alcohol prep wipe. Screw a foil-wrapped needle from the box onto the threaded tip.
- Prime the needle. Dial up 1 click, point the needle upwards, press the dose button. A drop of solution at the needle tip confirms the pen is primed and any air is expelled.
- Dial your research dose. Each click on the dose dial delivers a fixed increment. Click resolution is typically 0.5–1 mg per click depending on calibration; the dose window shows your total dialled dose. For example, a 6 mg research dose is roughly 6–12 clicks.
- Administer at the route used in published research. Cohort protocols use subcutaneous administration (abdomen, thigh, upper arm). Hold for ~6 seconds before withdrawing.
- Discard the needle in a sharps container. Cap the pen and return to refrigerated storage.
One pen lasts the number of doses shown in the protocol cards above for your selected size. When it’s empty, drop a refill cartridge into the same pen body – price for your size is in the calculator at the top.
Research use only. Procedure drawn from published cohort protocols. We do not provide medical or human-use guidance.
Storage
Lyophilised vial: stable 24+ months at 2–8 °C, sealed and protected from light. Don’t freeze.
Reconstituted (after BAC water): ~30 days at 2–8 °C. Don’t shake. Keep in original glass vial. Discard if cloudy or discoloured.
BAC water bottle: 30 days once opened, refrigerated.
- Administration in research
Published research literature on Retatrutide uses subcutaneous administration in the abdomen, thigh or upper arm in human pharmacokinetic and Phase 2 / 3 studies. Researchers rotate sites between administrations to reduce local tissue stress.
Research use only. The route information above is drawn from published peer-reviewed literature for context. We do not provide human-use guidance, dosing protocols, or administration instructions.
Reference: Jastreboff et al. 2023 (NEJM)
- What should my dose be?
The clean answer: follow the protocol cards above. Published research literature on Retatrutide uses titration – start low, step up at fixed weekly intervals. The phase highlighted in green is where most published research cohorts settle for ongoing study.
If you’re new to this compound: start at Phase 1 (the lowest dose shown above) for the full duration of that phase, then step up to the next. The titration is what limits the GI side effects reported in the trial – don’t skip it.
If you’ve used this compound before: you already know which phase you’re at. Tap the phase tabs above to see exactly what your dose costs at your selected vial or pen size, plus how long it will last.
If your protocol is non-standard: WhatsApp us before you order. We help researchers work out custom schedules every day and will tell you which size makes most sense for the cadence you’re running. Real human reply, not a chatbot.
Research use only. The dosing described is drawn from published peer-reviewed cohort literature for context. We do not provide medical or human-use guidance. If you are evaluating this compound for human use, consult a qualified medical practitioner. Reference: Jastreboff et al. 2023 (NEJM)
About Retatrutide
Retatrutide (development code LY3437943) is a 39-amino-acid synthetic peptide engineered as a triple agonist at three of the four principal incretin and glucagon-related receptors: GLP-1, GIP, and glucagon. It carries a C20 fatty-diacid acylation that enables strong albumin binding and a serum half-life of approximately 6 days, supporting the once-weekly administration cadence used in published Phase 2 research literature.
In the published Phase 2 research (Jastreboff et al., NEJM 2023), Retatrutide produced the largest body-weight outcomes of any single-compound incretin programme reported to date, distinguishing the triple-agonist class from dual agonists like Tirzepatide and single-target agonists like Semaglutide.
Chemical & reference data
| Class | GLP-1 / GIP / glucagon triple receptor agonist (acylated peptide) |
| CAS number | 2381089-83-2 |
| Molecular weight | 4731.43 g/mol |
| Sequence length | 39 amino acids |
| Reported half-life | ~6 days (~144 hours) in published research |
| Stability (lyophilised) | 24+ months at 2–8 °C, sealed and protected from light |
| Stability (reconstituted) | ~30 days at 2–8 °C in bacteriostatic water |
| Receptor targets | GLP-1R, GIPR, GCGR |
| Primary citation | Jastreboff et al. 2023 (NEJM) |
About Retatrutide
Retatrutide (development code LY3437943) is a 39-amino-acid synthetic peptide engineered as a triple agonist at three of the four principal incretin and glucagon-related receptors: GLP-1, GIP, and glucagon. It carries a C20 fatty-diacid acylation that enables strong albumin binding and a serum half-life of approximately 6 days, supporting the once-weekly administration cadence used in published Phase 2 research literature.
In the published Phase 2 research (Jastreboff et al., NEJM 2023), Retatrutide produced the largest body-weight outcomes of any single-compound incretin programme reported to date, distinguishing the triple-agonist class from dual agonists like Tirzepatide and single-target agonists like Semaglutide.
Chemical & reference data
| Class | GLP-1 / GIP / glucagon triple receptor agonist (acylated peptide) |
| CAS number | 2381089-83-2 |
| Molecular weight | 4731.43 g/mol |
| Sequence length | 39 amino acids |
| Reported half-life | ~6 days (~144 hours) in published research |
| Stability (lyophilised) | 24+ months at 2–8 °C, sealed and protected from light |
| Stability (reconstituted) | ~30 days at 2–8 °C in bacteriostatic water |
| Receptor targets | GLP-1R, GIPR, GCGR |
| Primary citation | Jastreboff et al. 2023 (NEJM) |
FAQ
- What is the deference between the vial and the pen?
The compound inside is identical: same Retatrutide, same Janoshik-verified batch, same purity. The vial is a clear glass vial of lyophilised powder that you reconstitute yourself with bacteriostatic water; the pen is the same compound pre-loaded into a research injector pen with a dose dial, ready to use. The pen costs £15 more than the equivalent vial (the refill-service charge for filling and assembling the pen).
- What happens when i run out?
If you ordered a vial: just order another vial at the normal vial price. Add bacteriostatic water (£6) only if you’ve also run low on it. We dispatch same-day on UK weekday orders before 2pm.
If you ordered a pen: order a refill cartridge at vial price + £15 (refill service). The cartridge slots straight into your existing pen, so you don’t need to buy a new pen device every time. The maths is laid out for you in the calculator above.
- Why Bank Transfer only?
Mainstream payment processors (Stripe, PayPal, the major card acquirers) classify research-chemical suppliers as high-risk and decline our category outright. UK Faster Payments via bank transfer settles in seconds, doesn’t add card-processing fees to your order, and means no card data is stored. We’re working on UK Open Banking integration.
- Is this for human use?
No. Retatrutide is supplied strictly as a research-grade reference reagent for in-vitro laboratory research only, the same legal frame as Sigma-Aldrich, Cayman Chemical or Tocris. We do not provide dosing guidance for humans, administration protocols, or any content relating to therapeutic use. Read the UK legality guide ›
- How discrete is the packaging?
Royal Mail outer is plain brown kraft cardboard with no branding visible from outside. Inside: your vial(s) in protective packaging, your printed Janoshik COA where applicable, ten insulin syringes for vial orders, four sterile alcohol prep wipes, and a small printed handling-and-reconstitution card on the inside of the lid. Nothing on the outside identifies the contents.
Related & comparisons
- Tirzepatide · dual GIP / GLP-1 agonist
- Semaglutide · single GLP-1 agonist
- Semaglutide vs Retatrutide · single vs triple receptor comparison
- Browse all metabolic research compounds ›
| SIZE | 10mg, 20mg, 40mg |
|---|
Be the first to review “Retatrutide.”
Related products
-
5-Amino-1MQ.
Price range: £41.00 through £76.00 Select options This product has multiple variants. The options may be chosen on the product page -
MOTS-c.
£65.00 Select options This product has multiple variants. The options may be chosen on the product page -
AOD-9604.
£63.00 Select options This product has multiple variants. The options may be chosen on the product page -
Tirzepatide
Price range: £85.00 through £205.00 Select options This product has multiple variants. The options may be chosen on the product page
Reviews
There are no reviews yet.